TirzepatideDosing & Reconstitution Calculator
Tirzepatide (Mounjaro, Zepbound) — Dose Dependent Weight Loss
Tirzepatide activates two of the hormones your body releases to regulate appetite and fat storage — and it's the only FDA approved weight-loss drug that hits GIP at full native strength.⁷
- Appetite control — GLP-1 (0.2× native). GLP-1 is the hormone your gut releases after a meal to tell your brain "you're full." Tirzepatide hits this receptor at 20% of your body's own GLP-1 signal — significantly dialed back relative to semaglutide (1× native), which is why nausea and food aversion run lower on tirz than on sema at equipotent weight-loss doses.
- Fat-cell energy handling — GIP (1× native). GIP is the hormone that tells fat cells how to process incoming energy. Tirzepatide hits this receptor at full native strength, and in fat cells that triggers a heat-generating cycle — the fat cell pumps calcium, leaks it back, and burns ATP as heat (SERCA-mediated futile calcium cycling⁷).
That fat-cell thermogenesis is what produces tirzepatide's defining advantage: ~75:25 fat-to-lean loss ratio in non-diabetic obesity, versus semaglutide's ~60:40 at comparable total weight loss.³ The fat cell itself becomes a calorie sink. The drug shifts weight loss toward fat rather than relying on caloric deficit alone.
The dose question below has three variables: total weekly dose, injection frequency, and whether you're actively losing or maintaining. Tirzepatide is FDA-approved as Mounjaro (T2D) and Zepbound (obesity), so the ranges come from labeled titration schedules plus clinical practice for the maintenance-dose case.
Tirzepatide Dosing Math — The GIP Advantage
| Receptor | What it does | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|---|
| GLP-1R | Appetite suppression, gastric slowing | 1.0× | 0.2× | 0.4× |
| GIPR | Fat-cell energy handling, adipose thermogenesis | — | 1.0× | 8.9× |
| GCGR | Hepatic fat oxidation, energy expenditure | — | — | 0.3× |
Receptor affinity values from Coskun receptor pharmacology (⁸), normalized against the body's own hormone at each receptor.
Tirzepatide's GLP-1 signal is the softest of the three active GLP-1 drugs — dialed back on purpose. The heavy lifter is GIP at full native strength, driving the fat-cell thermogenesis (characterized in Cell Metabolism 2024⁷) that pure GLP-1 agonists can't touch at any dose.
The dose implication: the GIP arm fires at lower drug levels than the GLP-1 arm. Appetite suppression scales with GLP-1 occupancy, but GIP's fat-cell thermogenesis saturates earlier.⁸ That's why tirz's body-composition advantage (75:25 fat:lean in non-diabetic obesity³) is preserved at maintenance doses of 5–10mg, even though the appetite suppression at those doses is lighter than at 15mg. You can step down off MTD without losing the mechanism that made tirz worth choosing.
Tirzepatide's Phase 3 trial (SURMOUNT-1) produced 21% average weight loss at 15mg over 72 weeks in non-diabetic obesity,¹ and the head-to-head SURMOUNT-5 readout showed 20.2% on tirz vs 13.7% on sema at maximum doses — 47% more weight loss.² Readers focused on weight loss typically settle between 5 and 10mg weekly rather than pushing to the 15mg ceiling — covered in the dosing-math section below, along with why 5–10mg also works as the post-loss maintenance dose.
In type 2 diabetes, the "incretin defect" impairs GIP signaling at the receptor level, and the body-composition advantage narrows — head-to-head DXA shows nearly identical ratios on tirz and sema (~87:13 vs ~86:14).⁴ Tirz still produces more total fat loss in T2D, but the 75:25 ratio is a non-diabetic outcome. If you're T2D, your physiology matches the narrower-advantage trial population, not the SURMOUNT-1 obesity cohort.
This is the specific limitation that led Lilly to design retatrutide with 8.9× native GIP affinity and a glucagon arm to bypass impaired incretin signaling entirely. That glucagon arm also produces retatrutide's dose-dependent +6–7 bpm resting-HR signal at 12mg — a cardiac trade-off tirzepatide does not share. Tirz does not raise resting HR in SURPASS/SURMOUNT trial data, and SURPASS-CVOT showed no worsening of cardiovascular outcomes.
Weight loss isn't the only thing tirz does. SYNERGY-NASH tested tirz 15mg head-to-head against placebo for histologic MASH resolution — 62% of tirz patients hit resolution without worsening fibrosis versus 10% on placebo.¹⁰ SURPASS-3 MRI (47% hepatic fat reduction⁶) and SYNERGY-NASH (MASH resolution) are different endpoints measuring different things: liver fat content on imaging versus the histologic inflammation-plus-ballooning pattern that defines the disease. Both moved, which matters for the MASLD audience that most dosing pages ignore. The drug's extra-metabolic reach extended further still — SURMOUNT-OSA cut apnea-hypopnea index by roughly 25 events per hour in obstructive sleep apnea patients with obesity, which was enough for the FDA to approve tirz for OSA in 2024.¹¹ The drug does more than shrink waistlines; at this point it has histology and polysomnography data the older GLP-1s don't.
The tirzepatide deep dive covers the full trial cohorts, SURMOUNT-5 head-to-head data, and the body-composition analysis.
Figuring out the right Tirz dose for you
Three inputs shape the dose decision: what you're trying to do with the drug, what your baseline tolerates, and how your body responds in the first few weeks.
Before you start, check these
A baseline panel before your first injection makes every subsequent dose decision defensible. Without it, a shift in gallbladder symptoms or lipids at week 12 can't be distinguished from a drug effect.
- Fasting glucose, HbA1c, fasting insulin — the metabolic starting point. Tirz improves insulin efficiency via the GIP arm; these are how you'll tell whether the dose is moving the needle on what matters.
- Lipid panel — tirzepatide improves triglycerides and shifts the ApoB / non-HDL profile. A baseline matters for tracking the secondary metabolic effects even when weight loss is the primary goal.
- Liver enzymes, and imaging if MASLD is in the picture — tirz produces ~47% hepatic-fat reduction (SURPASS-3 MRI⁶). Pre-drug picture helps measure.
- Gallbladder history — tirz carries much lower biliary risk than semaglutide (no significant biliary signal in trials, vs sema's 2.6× cholelithiasis odds), but rapid weight loss still increases gallstone risk generally. Flag any prior cholecystitis or known gallstones.
- Oral contraceptive awareness — tirz's slowed gastric emptying reduces oral contraceptive absorption, most pronounced in the first 4 weeks after starting or after any dose increase. Use non-oral contraception or add a barrier method through each titration step.
- Medullary thyroid carcinoma or MEN2 history — hard contraindication across the GLP-1 class (rodent thyroid tumor signal; no confirmed human cases, but the label warning is firm).
Finding your effective Tirz dose: 2.5mg titration steps
The labeled Zepbound/Mounjaro ladder ramps over 20+ weeks. Hold each step for at least 4 weeks — and do not compress the first four weeks under any circumstance.
| Step | Weeks | Dose | What happens |
|---|---|---|---|
| 1 | 1–4 | 2.5mg | Tolerance testing. GI assessment. Minimal weight change — this is adaptation. |
| 2 | 5–8 | 5mg | First level with clear weight-loss momentum. Many users find this sufficient. |
| 3 | 9–12 | 7.5mg | Optional mid-step for GI sensitivity. Good balance of effect and tolerability. |
| 4 | 13–16 | 10mg | Strong effect band. Where most users who need more than 5mg stabilize. |
| 5 | 17–20 | 12.5mg | High dose for larger losses when tolerated. |
| 6 | 21+ | 15mg | Maximum. Full obesity-indication dose. |
The step-duration rule is pharmacokinetic, not stylistic. Tirz's half-life is roughly 5 days,⁷ so plasma concentration at a new dose step doesn't stabilize for two half-lives — 10 to 15 days. A GI response to dose N can arrive after you've already moved to dose N+1, and the next step loads on top of an unresolved reaction.
Pushing through the first four weeks is the single most common way to turn a manageable titration into a rough one. Even if you feel fine at week 2 on 2.5mg, the 5-day half-life means you haven't seen the full plasma response yet. GI side effects cluster during titration and diminish on maintenance — most users who discontinue tirz do so during escalation, not at steady-state.
Stopping rule during the climb: if nausea or GI distress from the previous step hasn't resolved, extend the step duration — do not layer. If gallbladder symptoms appear (right-upper-quadrant pain, especially post-meal), hold at current dose and evaluate before increasing.
Typical Tirz dose ranges, based on goals and needs
| Band | Dose | What you get | Who it fits |
|---|---|---|---|
| Low | 2.5–5mg | Glycemic control, modest weight loss, adaptation | Weeks 1–8 for everyone. Long-term maintenance band for many post-loss users (see next section). |
| Moderate | 7.5–10mg | ~15–20% weight loss, strong body-composition advantage | Most users targeting active weight loss. The 75:25 fat:lean ratio fires fully here. |
| High | 12.5–15mg | ~20–22% weight loss (SURMOUNT-1 average at 15mg¹) | Full obesity doses. About 57% reach ≥20%; 36% reach ≥25%. Step here only if the moderate band plateaus. |
The best dose is the lowest that keeps appetite controlled and weight trending down with acceptable side effects. GI burden scales with dose but the body-composition advantage fires at lower levels than the appetite-suppression arm — many users who drove active loss at 12.5–15mg step down to 5–7.5mg for maintenance without losing the fat-selective ratio.
What to track during the initial start phase
- Weight and waist circumference — weekly, same conditions (morning, fasted, post-void). Waist trend is the cleaner signal for visceral-fat response — weight alone conflates fat, water, and lean mass.
- Body composition (InBody or DXA) — if accessible, at baseline and every 3 months. Confirms the 75:25 ratio expectation is being met for your physiology.
- Fasting glucose, HbA1c, fasting insulin — quarterly.
- Lipid panel — quarterly.
- Liver enzymes — quarterly; more often if MASLD is in the picture.
- Gallbladder symptoms — ongoing. Right-upper-quadrant pain after fatty meals is the typical presentation. Tirz's biliary risk is lower than sema's, but rapid weight loss in general increases stone formation.
Tirz at 2.5mg: the metabolic-health use case
At 2.5mg weekly, tirzepatide triggers the same fat-cell thermogenesis that drives its 75:25 body-composition advantage — with minimal appetite suppression and minimal GI burden. This is tirz as a metabolic-health tool, not a weight-loss tool.
Three effects land at this dose without the side-effect load of therapeutic doses:
- Fat-cell thermogenesis still fires. GIP saturation happens at low drug levels (per the Dosing Math section above), so the heat-generating cycle that produces tirz's body-composition advantage is already active at 2.5mg. You get the fat-selective mechanism without needing the full appetite-suppression arm to fire.
- Glucose and lipid markers improve modestly. Tirz improves insulin efficiency, triglycerides, and the ApoB / non-HDL profile via the GIP arm. At 2.5mg, expect fasting insulin drops of ~10–15% and triglyceride reductions of ~5–10% — enough to move markers in someone who's metabolically borderline without pushing toward weight loss.
- Food noise quiets, hunger doesn't collapse. The GLP-1 arm at 0.2× native is already the softest among active GLP-1 drugs; at 2.5mg, the appetite-suppression signal is gentle. Users typically report eating normal meals without between-meal snacking, but the capacity to eat for training or recomposition is preserved.
This is the right dose band for someone at a healthy or mildly overweight baseline with metabolic markers to move (early insulin resistance, borderline lipids, elevated liver fat on imaging), an at-risk phenotype taking proactive measures (South Asian metabolic pattern, family history of T2D, PCOS with cardiometabolic concerns), or training-oriented and prioritizing body-composition quality over scale weight. For this reader, the GIP-driven benefits land without retatrutide's cardiac signal or investigational status — and without semaglutide's aggressive GLP-1 load.
The 2.5mg label dose was designed as the 4-week starting step of an active-weight-loss titration, not a long-term maintenance target. No RCT has formally tested sustained 2.5mg dosing as a standalone regime. The mechanistic basis is strong (Coskun receptor pharmacology⁸, Yu 2024 Cell Metab⁷, SURMOUNT-1 DXA dose-response³), but long-term data at this dose specifically is limited to community practice and extrapolation. GI burden at 2.5mg is lower than at 5mg+, but still non-zero — plan for 2–4 weeks of adaptation.
Tirz at 5mg: the maintenance case
Once you've reached goal weight on 10–15mg, the dose question flips. Staying at maximum-tolerated dose indefinitely usually isn't necessary. The standard tirzepatide maintenance dose is 5–10mg weekly — roughly half the peak dose that drove the initial loss.
The GIP-saturation logic above does the work: at 5mg, GIP is still firing at full thermogenic capacity, so the 75:25 body-composition advantage is preserved. What reduces at the lower dose is mostly GLP-1 appetite suppression — food noise drifts back from zero to manageable, gastric emptying speeds up modestly, between-meal hunger returns somewhat. For most maintainers that trade-off is welcome. The appetite flatness of MTD is uncomfortable long-term, and the body-composition mechanism that made tirz worth choosing still fires at the reduced dose.
Horn 2025 Obesity is the first RCT testing 5mg vs MTD maintenance; readout expected May 2026. Aronne 2024 SURMOUNT-4 showed 89.5% of participants who continued tirzepatide at their effective dose maintained at least 80% of their loss over 52 weeks, vs 14% regain on placebo switch⁹ — establishing that continuing at some dose matters more than the specific dose level.
Step-down rhythm: typically 15 → 10 → 7.5 → 5mg, holding each step 8–12 weeks to see whether weight drifts before reducing further. Some maintainers go lower — 2.5mg weekly, or 2.5–5mg every 10–14 days as schedule extension. That's community practice without RCT backing.
When NOT to step down: BMI still in the obese range (reduction is premature), hunger returns within 72h of injection (GLP-1 arm is doing more work than GIP in your body-comp profile), weight creeps more than 2 lb/month at the reduced dose, or training strength trends down despite protein adherence. In any of those cases, hold the higher dose and revisit in 8 weeks.
How often should you take tirzepatide? The case for splitting a weekly dose
Tirzepatide's 5-day half-life produces a more pronounced peak-trough curve on weekly dosing than semaglutide's 7-day. Community experience consistently reports a day 5–6 hunger dip — that's the trough, and for some users it's where maintenance failure shows up first. Splitting the weekly dose fills the valley and smooths GI load at each injection.
| Frequency | Injections/week | VSariance | Where it fits |
|---|---|---|---|
| Weekly (q7d) | 1 | Moderate-high | Trial protocol. Convenience-first. |
| Twice weekly (q3.5d) | 2 | Moderate | The default split. Reduces GI burden and fills the mid-week hunger valley. |
| Every 3 days (q3d) | ~2.3 | Low | Aligns closely with the 5-day half-life — smoothest curve for a modest injection count. |
| Every other day (q2d) | 3.5 | Lowest | Peak-sensitive users. Most needles. |
Splitting a 10mg weekly dose into two 5mg injections (q3.5d) cuts the injection-peak concentration roughly in half while delivering the same weekly total. GI side effects and the day-5–6 hunger dip both track peak concentration, not the weekly total — which is why splitting often resolves problems that simply cutting the dose cannot.
The GLP-1 Dosing Optimizer calculates the exact per-injection dose and plasma curve for any frequency.
How to Calculate Tirzepatide Dosage Manually
While the PeptideFox AI Wizard handles compound-specific titration logic automatically, it is crucial to understand the manual math behind your Tirzepatide dose.
To determine exactly how many "units" to draw on a standard U-100 insulin syringe, use the Standard Peptide Formula:
Volume to Draw (mL) = Desired Dose (mg) ÷ Vial Concentration (mg/mL)
Example: Calculating a 2.5mg Starting Dose
If you reconstitute a 10mg vial of Tirzepatide with 2mL of Bacteriostatic (BAC) Water, your vial concentration is 5mg/mL.
- Desired Dose: 2.5 mg (Standard Month 1 Initiation Dose)
- Vial Concentration: 5.0 mg/mL
- The Math: 2.5 ÷ 5.0 = 0.5 mL
- Syringe Units: 0.5 mL equals exactly 50 units on a U-100 syringe.
For seamless scaling through the 5mg, 7.5mg, and 10mg escalation phases, use the PeptideFox Reconstitution & Dosing Tool to generate a complete visual Audit Trail of your syringe.
Reconstituting tirzepatide with BAC water
Every Tirz vial is a fixed amount of peptide sitting at the bottom as a dry cake. Bacteriostatic water is what turns it into a solution you can draw and inject. The volume of water sets the concentration (mg per mL), and that concentration sets how far you pull the plunger for a given dose. More water means lower concentration and a larger, easier-to-read draw. Less water means higher concentration and a smaller injection volume. The total milligrams in the vial don't change — water is a measurement choice, not a potency factor.
New to reconstitution? The PeptideFox reconstitution guide walks through the full process — sterile technique, storage, troubleshooting — with images. Start there if this is your first vial.
How to reconstitute tirzepatide
The mechanics are simple but they matter. Rough handling denatures the peptide. Bad technique contaminates the whole vial.
- Wipe both stoppers (peptide vial and BAC water vial) with an alcohol swab.
- Calculate the amount of BAC water needed — use an amount that allows for easy dosing.
- Draw the BAC water into a sterile syringe.
- Angle the needle so water runs down the inside wall of the peptide vial — not directly onto the cake.
- Swirl gently. Do not shake. Mechanical agitation denatures peptides. A slow rocking motion dissolves the cake in 30–60 seconds.
- Refrigerate at 2–8°C between draws. Never freeze reconstituted tirz — freeze-thaw cycles damage the peptide structure.
- Discard if the solution turns cloudy, discolored, or shows visible particles.
- Use a fresh syringe and wipe the stopper with alcohol at every draw.
Reconstituted tirzepatide is stable 4–6 weeks at 2–8°C. Some sources extend to 8 weeks with strict sterile technique.
Where the vials come from
Tirzepatide is FDA-approved as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023) — both dispensed as pre-filled single-dose pens. Compounded tirzepatide, prepared by 503A or 503B pharmacies during the FDA-declared shortage, arrives as a lyophilized powder requiring reconstitution. The compounding landscape has tightened post-shortage: many 503A pharmacies have exited and the remaining 503B outsourcing facilities operate under stricter federal oversight. Ask your supplier for a certificate of analysis before your first order.
Choosing the right vial size
Match vial size to your weekly dose and the 4–6 week reconstituted stability window. At 2.5mg weekly: 5mg or 10mg vial. At 5mg: 10mg or 20mg. At 7.5–10mg: 20mg or 30mg. At 12.5–15mg: 30mg, 40mg, 50mg, or 60mg. Larger vials only make economic sense at higher weekly doses — a 60mg vial at 5mg weekly holds 12 weeks of drug, well past stability.
FAQ
What is the recommended tirzepatide dosage?
How much BAC water do I add to a 5 mg tirzepatide vial?
How much BAC water do I add to a 10 mg tirzepatide vial?
How much BAC water do I add to a 15 mg tirzepatide vial?
How much BAC water do I add to a 20 mg tirzepatide vial?
How much BAC water do I add to a 30 mg tirzepatide vial?
How much BAC water do I add to a 40 mg tirzepatide vial?
How much BAC water do I add to a 50 mg tirzepatide vial?
How much BAC water do I add to a 60 mg tirzepatide vial?
How do I convert syringe units to milliliters?
Related Topics
- Tirzepatide Deep Dive — mechanism, trial data, body-composition analysis, SURMOUNT-5 head-to-head
- GLP-1 Dosing Optimizer — interactive frequency calculator with plasma curves
- Full Reconstitution Calculator — all peptides, cocktails, custom BAC volumes
- GLP-1 Muscle Preservation — protect lean mass during weight loss
- Semaglutide Dosing — the established GLP-1 benchmark
- Retatrutide Dosing — the investigational triple-agonist
References
¹ Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022. SURMOUNT-1 — 21% average weight loss at 15mg over 72 weeks in non-diabetic obesity.
² Frías JP, et al. Tirzepatide versus Semaglutide. NEJM 2024. SURMOUNT-5 — 20.2% vs 13.7% at maximum doses; 47% greater weight loss than semaglutide.
³ SURMOUNT-1 DXA body-composition substudy: Diabetes Obes Metab 2024 — 75:25 fat-to-lean ratio at 15mg in non-diabetic obesity versus ~60:40 on semaglutide in STEP-1.
⁴ Clamp Study — head-to-head body composition in T2D (tirzepatide vs semaglutide): Diabetes Res Clin Pract 2023 — 87:13 vs 86:14 fat-to-lean ratio in T2D; GIP-driven advantage blunted by the incretin defect.
⁵ Frías JP, et al. SURPASS-2. NEJM 2021. SURPASS-2 — tirz 15mg vs sema 1mg in T2D; ~13% vs ~6% weight loss at 40 weeks.
⁶ SURPASS-3 MRI substudy: Lancet Diabetes Endocrinol 2025 — liver fat, visceral fat, and muscle quality on tirzepatide.
⁷ Yu R, et al. GIP receptor futile calcium cycling in adipocytes. Cell Metabolism 2024. Cell Metab — SERCA-mediated adipose thermogenesis; mechanism of the GIP body-composition advantage. Also covers ~5-day half-life.
⁸ Coskun T, et al. Tirzepatide receptor pharmacology — imbalanced agonism. Receptor affinity profile (GLP-1 0.2× native, GIP 1.0× native) and basis for GIP-first signaling at sub-MTD doses. Nauck et al. Lancet 2021 review covers the imbalanced-agonism framework.
⁹ Aronne LJ, et al. SURMOUNT-4 — maintenance of weight loss with tirzepatide. JAMA 2024. SURMOUNT-4 — 89.5% of continuators held ≥80% of loss over 52 weeks; 14% regain on placebo switch. Anchor for maintenance-dose logic.
¹⁰ Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. NEJM 2024. SYNERGY-NASH (PMID 38856224) — 62% MASH resolution at tirz 15mg vs 10% placebo; histologic endpoint distinct from SURPASS-3 MRI hepatic fat content.
¹¹ Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. NEJM 2024. SURMOUNT-OSA — AHI reduction of ~25 events/hour at 15mg; basis for FDA approval of tirz for moderate-to-severe OSA with obesity in December 2024.
Medical Disclaimer
The content in this calculator is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.